These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 11672449

  • 1. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women.
    Maffei S, Del Ry S, Prontera C, Clerico A.
    Clin Sci (Lond); 2001 Nov; 101(5):447-53. PubMed ID: 11672449
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 5. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
    Chu MC, Cosper P, Nakhuda GS, Lobo RA.
    Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346
    [Abstract] [Full Text] [Related]

  • 6. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice.
    Buckley MG, Marcus NJ, Yacoub MH.
    Clin Sci (Lond); 1999 Dec; 97(6):689-95. PubMed ID: 10585896
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V, Sarti CD, Fornaro F, Farzati A, De Franciscis P, Sepe E, Borrelli AL, Colacurci N.
    Menopause; 2003 Dec; 10(4):286-91. PubMed ID: 12851511
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Changes of nitric oxide and endothelin plasma levels and effects of hormone replacement therapy in postmenopausal women].
    Lai A, Zhang J, Ding L.
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):222-4. PubMed ID: 11776165
    [Abstract] [Full Text] [Related]

  • 10. Skin contamination by oestradiol gel--a remarkable source of error in plasma oestradiol measurements during percutaneous hormone replacement therapy.
    Vihtamäki T, Luukkaala T, Tuimala R.
    Maturitas; 2004 Aug 20; 48(4):347-53. PubMed ID: 15283926
    [Abstract] [Full Text] [Related]

  • 11. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T, Ishikita T, Matsuura H, Saji T.
    J Cardiol; 2001 Nov 20; 38(5):263-71. PubMed ID: 11729726
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of hormone therapy on the enteroinsular axis.
    Sztefko K, Rogatko I, Milewicz T, Józef K, Tomasik PJ, Szafran Z.
    Menopause; 2005 Nov 20; 12(5):630-638. PubMed ID: 16145319
    [Abstract] [Full Text] [Related]

  • 14. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J, Sumino H, Ichikawa S, Ozaki M.
    Am J Hypertens; 2006 Jul 20; 19(7):744-9. PubMed ID: 16814131
    [Abstract] [Full Text] [Related]

  • 15. Serum leptin levels and body weight in postmenopausal women under transdermal hormone replacement therapy.
    Salbach B, Nawroth PP, Kübler W, von Holst Th, Salbach PB.
    Eur J Med Res; 2000 Feb 28; 5(2):63-6. PubMed ID: 10720565
    [Abstract] [Full Text] [Related]

  • 16. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.
    Climacteric; 2002 Dec 28; 5(4):341-50. PubMed ID: 12626213
    [Abstract] [Full Text] [Related]

  • 17. Hormone replacement therapy: one-year follow up of DNA damage.
    Casella M, Manfredi S, Andreassi MG, Vassalle C, Prontera C, Simi S, Maffei S.
    Mutat Res; 2005 Aug 01; 585(1-2):14-20. PubMed ID: 15996896
    [Abstract] [Full Text] [Related]

  • 18. [The examination of clinical prognostic importance of atrial and brain natriuretic peptide in patients with acute myocardial infarction].
    Mazurek W, Salomon P.
    Pol Merkur Lekarski; 2002 Jan 01; 12(67):15-9. PubMed ID: 11957795
    [Abstract] [Full Text] [Related]

  • 19. Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice.
    Buckley MG, Marcus NJ, Yacoub MH, Singer DR.
    Clin Sci (Lond); 1998 Sep 01; 95(3):235-9. PubMed ID: 9730841
    [Abstract] [Full Text] [Related]

  • 20. Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension.
    Soualmia H, Ayadi I, Omar S, Feki M, Drissa H, Mebazaa A, Kaabachi N.
    Clin Lab; 2009 Sep 01; 55(3-4):120-7. PubMed ID: 19462934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.